Table 2 The CIs at 90% effect level of the drug combinations
Therapeutic drug | Inhibitor | Cell line | Cell line sensitivity to therapeutic drug | CI at 90% effect level | Effect |
|---|---|---|---|---|---|
Cisplatin | Bortezomib | NCI-H23 | Sensitive | 1.30 | Moderate antagonism |
| Â | Â | U-2020 | Resistant | 0.61 | Synergism |
| Â | b-AP15 | NCI-H23 | Sensitive | 0.41 | Synergism |
| Â | Â | U-2020 | Resistant | 0.72 | Moderate synergism |
Gefitinib | Bortezomib | U-2020 | Sensitive | ND | ND |
| Â | Â | NCI-H23 | Resistant | 0.37 | Synergism |
| Â | b-AP15 | U-2020 | Sensitive | ND | ND |
| Â | Â | NCI-H23 | Resistant | ND | ND |
Gemcitabine | Bortezomib | NCI-H23 | Sensitive | 0.32 | Synergism |
| Â | Â | U-1752 | Resistant | 0.28 | Strong synergism |
| Â | b-AP15 | NCI-H23 | Sensitive | ND | ND |
| Â | Â | U-1752 | Resistant | 0.56 | Synergism |
Vinorelbine | Bortezomib | NCI-H23 | Sensitive | 0.94 | Nearly additive |
| Â | Â | U-2020 | Resistant | 0.38 | Synergism |
| Â | b-AP15 | NCI-H23 | Sensitive | 0.63 | Synergism |
| Â | Â | U-2020 | Resistant | 0.55 | Synergism |